

BIOENVISION INC  
Form 8-K  
October 23, 2007

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

**DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):**

**October 22, 2007**

**GENZYME CORPORATION**

(Exact name of registrant as specified in its charter)

**Massachusetts**  
(State or other jurisdiction of  
incorporation or organization)

**0-14680**  
(Commission file number)

**06-1047163**  
(IRS employer identification  
number)

**500 Kendall Street, Cambridge, Massachusetts 02142**

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code:

**(617) 252-7500**

## Edgar Filing: BIOENVISION INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other Events.**

On October 22, 2007, Genzyme Corporation announced that the stockholders of Bioenvision, Inc. voted to approve the merger of Wichita Bio Corporation, a wholly-owned subsidiary of Genzyme, with and into Bioenvision. The merger was effective as of 12:01AM EST on October 23, 2007. A copy of the press release is included as Exhibit 99.1 hereto.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**GENZYME CORPORATION**

Dated: October 22, 2007

By: /s/ Peter Wirth  
Peter Wirth  
Executive Vice President and  
Chief Legal Officer

**Item 9.01 Financial Statements and Exhibits.**

(c) Exhibits

99.1 Press Release of Genzyme Corporation dated October 22, 2007.